Eversept Partners, LP — 13F Holdings & Portfolio

CIK 1697013 · latest 13F-HR filed 2026-08-14

Eversept Partners, LP manages $1.93B in 13F-reported U.S. long-equity assets across 120 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are UTHR (8.09%), ABVX (6.32%), EHC (5.38%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 32 new positions and exited 21; 47 existing positions rose in reported value and 30 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.93B

Long-equity book

Holdings
120

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+32 / −21 / ↑47 / ↓30

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 46.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$2.65B
Discretionary
$2.65B
Employees
10
Accounts
9
Address
444 MADISON AVENUE
22ND FLOOR
NEW YORK, NY 10022
Phone
(212) 271-4200
Name Title / Status Ownership Type
MOGHTADERI, KAMRAN, (NMN) ControlMANAGING PRINCIPAL
since Sep 2015
75% or moreIndividual
ROSENSTRAUS, RON, AVI ControlCHIEF FINANCIAL OFFICER
since Jan 2023
Less than 5%Individual
SHAH, RISHI, RASESH ControlPRESIDENT
since Jan 2023
Less than 5%Individual
ZIHNALI, BALKIR, (NMN) ControlCHIEF COMPLIANCE OFFICER & CHIEF OPERATING OFFICER
since Mar 2020
Less than 5%Individual
EVERSEPT 1 LLCMEMBER
since Nov 2016
Less than 5%Domestic Entity
MOGHTADERI, KAMRAN, (NMN) Control
Indirect owner via EVERSEPT 1 LLC
MANAGING MEMBER
since Nov 2016
75% or moreIndividual
Ownership & leadership changes · 5 filings with changes since Mar 31, 2016

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 25, 2024 filing
  • ChangedZIHNALI, BALKIR, (NMN) · title CHIEF COMPLIANCE OFFICER → CHIEF COMPLIANCE OFFICER & CHIEF OPERATING OFFICER
Mar 24, 2023 filing
  • AddedROSENSTRAUS, RON, AVI · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • AddedSHAH, RISHI, RASESH · PRESIDENT · Less than 5% · control person
Mar 30, 2020 filing
  • AddedZIHNALI, BALKIR, (NMN) · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedMOGHTADERI, KAMRAN, (NMN) · title CHIEF COMPLIANCE OFFICER, MANAGING MEMBER → MANAGING PRINCIPAL
Jan 9, 2017 filing
  • ChangedMOGHTADERI, KAMRAN, (NMN) · now a control person
Nov 30, 2016 filing
  • AddedEVERSEPT 1 LLC · MEMBER · Less than 5%
  • AddedMOGHTADERI, KAMRAN, (NMN) · MANAGING MEMBER · 75% or more · indirect via EVERSEPT 1 LLC · control person
  • ChangedMOGHTADERI, KAMRAN, (NMN) · title MANAGING MEMBER → CHIEF COMPLIANCE OFFICER, MANAGING MEMBER
Mar 31, 2016 filing (earliest on record)
  • ListedMOGHTADERI, KAMRAN, (NMN) · MANAGING MEMBER · 75% or more

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 47 →

Top Trims

Show all 30 →

Eversept Partners, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $155.9M 8.09% 287,668 SH
2 ABIVAX SA ABVX 00370M103 $121.8M 6.32% 913,880 SH
3 ENCOMPASS HEALTH CORP EHC 29261A100 $103.8M 5.38% 1,026,919 SH
4 ENSIGN GROUP INC ENSG 29358P101 $96.5M 5.01% 602,079 SH
5 VERA THERAPEUTICS INC VERA 92337R101 $94.9M 4.93% 2,212,770 SH
6 INVESCO QQQ TR Put QQQ 46090E103 $72.6M 3.77% 98,600 SH
7 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $66.5M 3.45% 1,785,941 SH
8 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $61.2M 3.17% 2,798,210 SH
9 BROOKDALE SR LIVING INC BKD 112463104 $54.6M 2.84% 3,396,470 SH
10 IONIS PHARMACEUTICALS INC IONS 462222100 $52.7M 2.73% 664,684 SH
11 NATERA INC NTRA 632307104 $47.7M 2.48% 175,807 SH
12 TRAVERE THERAPEUTICS INC TVTX 89422G107 $45.4M 2.35% 798,973 SH
13 CARETRUST REIT INC CTRE 14174T107 $43.3M 2.24% 1,072,015 SH
14 HCA HEALTHCARE INC HCA 40412C101 $38.3M 1.99% 98,252 SH
15 VAXCYTE INC PCVX 92243G108 $36.6M 1.90% 629,952 SH
16 LIQUIDIA CORPORATION LQDA 53635D202 $34.2M 1.77% 428,652 SH
17 COMMUNITY HEALTH SYS INC NEW CYH 203668108 $26.3M 1.36% 7,864,575 SH
18 GSK PLC GSK 37733W204 $25.3M 1.31% 481,833 SH
19 CHEMED CORP NEW CHE 16359R103 $24.5M 1.27% 52,523 SH
20 ELI LILLY & CO LLY 532457108 $24.1M 1.25% 20,116 SH
21 GERON CORP GERN 374163103 $24.0M 1.24% 18,717,422 SH
22 VIKING THERAPEUTICS INC VKTX 92686J106 $23.5M 1.22% 602,922 SH
23 OMEGA HEALTHCARE INVS INC OHI 681936100 $23.1M 1.20% 483,547 SH
24 INSULET CORP PODD 45784P101 $22.7M 1.18% 148,816 SH
25 TENET HEALTHCARE CORP THC 88033G407 $21.4M 1.11% 114,199 SH
26 UNITEDHEALTH GROUP INC UNH 91324P102 $21.3M 1.10% 51,145 SH
27 WELLTOWER INC WELL 95040Q104 $19.8M 1.03% 87,312 SH
28 BETA BIONICS INC BBNX 08659B102 $19.6M 1.02% 1,249,441 SH
29 COGENT BIOSCIENCES INC COGT 19240Q201 $19.0M 0.98% 490,235 SH
30 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $18.7M 0.97% 1,865,653 SH
31 MOLINA HEALTHCARE INC MOH 60855R100 $18.4M 0.96% 80,594 SH
32 PENNANT GROUP INC PNTG 70805E109 $17.0M 0.88% 460,272 SH
33 LTC PPTYS INC LTC 502175102 $16.2M 0.84% 420,640 SH
34 INSMED INC INSM 457669307 $15.9M 0.83% 149,209 SH
35 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $15.3M 0.79% 831,142 SH
36 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $14.3M 0.74% 249,607 SH
37 AMN HEALTHCARE SVCS INC AMN 001744101 $13.9M 0.72% 428,531 SH
38 CELCUITY INC CELC 15102K100 $13.4M 0.69% 127,931 SH
39 PHARVARIS N V PHVS N69605108 $13.4M 0.69% 386,383 SH
40 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $13.3M 0.69% 3,558,497 SH
41 HUMANA INC HUM 444859102 $12.4M 0.64% 31,171 SH
42 XENON PHARMACEUTICALS INC XENE 98420N105 $11.9M 0.62% 196,532 SH
43 CORVUS PHARMACEUTICALS INC CRVS 221015100 $11.2M 0.58% 747,994 SH
44 ASCENDIS PHARMA A/S ASND K08588103 $11.1M 0.58% 41,621 SH
45 BRUKER CORP BRKR 116794108 $11.0M 0.57% 182,894 SH
46 MODERNA INC MRNA 60770K107 $10.7M 0.55% 152,122 SH
47 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $10.5M 0.55% 196,302 SH
48 INSMED INC Call INSM 457669307 $10.3M 0.53% 96,600 SH
49 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $10.2M 0.53% 217,185 SH
50 COMPASS PATHWAYS PLC CMPS 20451W101 $9.5M 0.49% 672,825 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.93B 120 0001697013-26-000005
2026-03-31 2026-05-15 $1.90B 120 0001697013-26-000003
2025-12-31 2026-02-17 $1.98B 107 0001697013-26-000002
2025-09-30 2025-11-14 $1.45B 86 0001697013-25-000010
Filer Information
Address
444 MADISON AVENUE
22ND FLOOR
NEW YORK, NY 10022
Phone
(212) 271-4200
Filing Manager
Eversept Partners, LP
NEW YORK, NY
Signatory
Ron Rosenstraus
Chief Financial Officer